Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microvascular Dysfunction.

NCT05492110 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2025-04-03

No results posted yet for this study

Summary

To demonstrate the feasibility and efficacy of the CS Reducer for the treatment of patients with ischaemia and non-obstructed coronary arteries (INOCA) and coronary microvascular dysfunction (CMD) and through a nested mechanistic substudy investigate the physiological responses in the coronary microcirculation responsible for changes in myocardial perfusion.

Conditions

  • Refractory Angina
  • Microvascular Angina
  • Microvascular Coronary Artery Disease
  • Coronary Disease
  • Angina Pectoris

Interventions

DEVICE

Coronary sinus reducer

The Neovasc coronary sinus reducer is an hourglass-shaped stainless steel device inserted percutaneously into the coronary sinus and currently indicated for the treatment of refractory angina.

OTHER

Sham-procedure

Implantation procedure with no device implanted

DIAGNOSTIC_TEST

Invasive coronary physiology

Invasive coronary physiology assessment as part of REMEDY-MECH mechanistic substudy

Sponsors & Collaborators

  • Bradford Teaching Hospitals NHS Foundation Trust

    collaborator OTHER_GOV
  • East and North Hertfordshire NHS Trust

    collaborator OTHER_GOV
  • Epsom and St Helier University Hospitals NHS Trust

    collaborator OTHER
  • Guy's and St Thomas' NHS Foundation Trust

    collaborator OTHER
  • Imperial College Healthcare NHS Trust

    collaborator OTHER
  • Kingston Hospital NHS Trust

    collaborator OTHER
  • London North West Healthcare NHS Trust

    collaborator OTHER
  • Oxford University Hospitals NHS Trust

    collaborator OTHER
  • Royal Brompton & Harefield NHS Foundation Trust

    collaborator OTHER
  • St George's University Hospitals NHS Foundation Trust

    collaborator OTHER
  • Liverpool University Hospitals NHS Foundation Trust

    collaborator OTHER_GOV
  • Imperial College London

    lead OTHER

Principal Investigators

  • Ranil E de Silva, FRCP, PhD · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-17
Primary Completion
2026-03-06
Completion
2026-03-06

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05492110 on ClinicalTrials.gov